Clinical Trial Goal
To find out:
- The highest dose of BL-M11D1 that's safe to give
- If BL-M11D1 is safe and works well to treat AML that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have AML that has relapsed or is refractory
- Have cancer cells with marker CD33 (CD33+). Your doctor can tell you this
- Do not have acute promyelocytic leukemia
- Do not have chronic myeloid leukemia (CML)
- Do not have graft-versus-host-disease (GVHD)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
BL-M11D1 is an antibody-drug conjugate (ADC) that targets CD33 on certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- BL-M11D1 – Given as an intravenous (IV) infusion 1 time
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has not yet approved BL-M11D1.
Contacts
Loren VanPelt, 4254536841, loren.vanpelt@systimmune.com
Whitney Eakins, whitney.eakins@systimmune.com
Locations
Sponsors
lead: SystImmune Inc.
